Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;12(10):607-19.
doi: 10.1038/nrclinonc.2015.129. Epub 2015 Jul 28.

First-line chemotherapy for mCRC—a review and evidence-based algorithm

Chiara Cremolini  1 , Marta Schirripa  1 , Carlotta Antoniotti  1 , Roberto Moretto  1 , Lisa Salvatore  1 , Gianluca Masi  1 , Alfredo Falcone  1 , Fotios Loupakis  1
Affiliations
Review

First-line chemotherapy for mCRC—a review and evidence-based algorithm

Chiara Cremolini et al. Nat Rev Clin Oncol. 2015 Oct.

Abstract

The response to first-line therapy is a primary determinant of outcome in patients with metastatic colorectal cancer (mCRC), for three main reasons: effective upfront therapy provides a unique opportunity to cure some patients; can be crucial in delaying disease progression and achieving symptom relief; and can improve patient eligibility for, and the effectiveness of, further treatments. In the past decade, decision-making regarding the choice of first-line therapy for mCRC has been complicated by the availability of many different options without a definitive consensus on a specific standard of care (despite major advances in categorizing predictive molecular disease subtypes). Most of the efforts of the scientific community have been directed at establishing the best biologic agent to be combined with a chemotherapy doublet, although a different branch of research has produced new data that underscore the importance of defining the optimal chemotherapy backbone. Herein, we review the key clinical trials completed in the past 10 years that have investigated and compared the use of chemotherapy doublets, triplets, and monotherapies, with or without molecularly targeted biologic agents, in the first-line treatment of patients with mCRC. Our examination of the literature led us to propose a new patient-oriented algorithm to guide clinicians' decisions on the best choice of upfront therapy for mCRC.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lancet. 2015 May 9;385(9980):1843-52 - PubMed
    1. Lancet. 2007 Jul 14;370(9582):143-52 - PubMed
    1. Br J Cancer. 2010 Nov 9;103(10 ):1542-7 - PubMed
    1. Ann Oncol. 2015 Apr;26(4):709-14 - PubMed
    1. J Clin Oncol. 2015 Mar 1;33(7):692-700 - PubMed

MeSH terms